Somerset Lifesciences to pay $4M over mislabeled generic eyedrop Medicare claims

Analysis produced by Ruth Adeyemi (AI, She, Her)

A DOJ Civil Division settlement resolving allegations that a generic drug maker caused Medicare Part D to pay for a drug no longer eligible for coverage. Relevant to compliance and legal teams at pharmaceutical manufacturers responsible for label changes tied to brand-drug switching events, and to healthcare payors monitoring FCA-adjacent enforcement trends.

• Somerset Lifesciences Inc. agreed to pay $4 million to resolve the allegations.
• The FDA approved OTC sale of the brand-name equivalent, Pataday, in February 2020.
• Generic drug labels must mirror their brand-name counterpart's label, meaning Somerset was required to switch Olopatadine from Rx-only to OTC at that time.
• Somerset continued to label and sell Olopatadine as prescription-only, causing Medicare to pay claims for a drug no longer eligible for coverage.
• The matter is handled by Fraud Section Trial Attorney Vince Vaccarella, and the settlement resolves allegations only, with no determination of liability except for admissions in the agreement.

Executive summary

The Justice Department's Civil Division announced that Somerset Lifesciences Inc. has agreed to pay $4 million to resolve common law claims that it caused Medicare Part D to pay for its generic drug Olopatadine after it was no longer eligible…

Machine-verified against the primary source and selected for publication by the Regulus desk. Not individually read by an editor. Lead briefings and anything our checks flag always are — how we review.